RWD Study in HER2+ mBC Patients in Third-Line Therapy
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer Stage IV
Interventions: OTHER: No intervention
Sponsor: Exactis Innovation
Collaborators: Knight Therapeutics